Peyronies Disease

Peyronie's disease (PD) is an inflammatory condition characterized by the formation of fibrous, noncompliant nodules in the tunica albuginea which can impede tunical expansion during penile erection, leading to deformity and bending. While the cause of this disease is thought to be due to microvascular trauma and abnormal wound healing, other hypotheses include genetic predisposition. In this review the pathophysiology of Peyronie's disease is discussed as well as current hypothese regarding its origin. Furthermore, there were significant associations between the risk factors for ED and PD, and with significant associations reported between PD and age, obesity, smoking, duration and number of cigarettes smoked per day. Dyslipidaemia, psychological disorders and the presence of at least one risk factor were significantly associated with PD. There were significant associations between a longer duration and poor metabolic control of diabetes and PD.

There is one medication approved by the Food and Drug Administration for the of Peyronie's disease. It's called collagenase Clostridium histolyticum (Xiaflex). The works by breaking down the buildup of collagen that causes penile curvature. It involves a series of in-office injections, directly into the penile lump, as well as penile modeling — brief exercises to gently stretch and straighten the penis. In clinical trials, this collagenase therapy significantly reduced curvature and bothersome symptoms associated with Peyronie's disease in many participants. Oral medication called pentoxifylline (Trental), verapamil (injections or topical gel) and interferon (injections).

‘Mayo clinic’ and other organizations along with the government encouraging many projects regarding the cure and further detailed studies of the disease.

The disease’s prevalence was found to be 9.7% and appeared to increase with age. In a follow-up study of 75 men, 30% reported a worsening of their signs and symptoms over time.